Form D · Biotechnology
Panome Bio Inc.
Saint Louis, MO · CIK 0001966691
Offering snapshot reported Nov 21, 2024 · SEC filing
- Reported sold
- $6M Offering amount: $6M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Nov 14, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 21, 2024 | Initial | $6,000,000 | No comparison | 6 | SEC filing |
| Feb 24, 2023 | Initial | $5,973,835 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-530044
Source: Form D, filed Nov 21, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rob Capone | Director |
| Tom Cohen | Executive |
| Alexander Herzick | Director |
| Deval Lashkari | Director |
| David Smoller | Director |
| Edward Weinstein | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4340 Duncan Avenue
Saint Louis, MO, 63110
Saint Louis, MO, 63110